CytoMed Therapeutics Limited Ordinary Shares Total Assets
CytoMed Therapeutics Limited Ordinary Shares total assets. Based on the latest financial reports, CytoMed Therapeutics Limited Ordinary Shares (GDTC) holds total assets worth $7.98 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CytoMed Therapeutics Limited Ordinary Sh (GDTC) total market value for the company's overall valuation and market capitalisation.
Total Assets of CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Total assets of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025. This chart illustrates how CytoMed Therapeutics Limited Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See CytoMed Therapeutics Limited Ordinary Sh (GDTC) share price today for real-time trading data and today's change.
CytoMed Therapeutics Limited Ordinary Shares - Asset Composition Analysis
CytoMed Therapeutics Limited Ordinary Shares Total Assets Breakdown (December 2025)
CytoMed Therapeutics Limited Ordinary Shares total assets breakdown as of December 2025. CytoMed Therapeutics Limited Ordinary Shares's total assets of $7.98 Million consist of 45.9% current assets and 54.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.2% |
| Accounts Receivable | $103.86K | 1.3% |
| Inventory | $1.07 Million | 13.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $124.54K | 1.6% |
| Goodwill | $355.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how CytoMed Therapeutics Limited Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CytoMed Therapeutics Limited Ordinary Sh working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CytoMed Therapeutics Limited Ordinary Shares's current assets represent 45.9% of total assets in 2025, an increase from 18.7% in 2019.
- Cash Position: Cash and equivalents constituted 26.2% of total assets in 2025, up from 12.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 13.4% of total assets.
CytoMed Therapeutics Limited Ordinary Shares Competitors by Total Assets
Key competitors of CytoMed Therapeutics Limited Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
CytoMed Therapeutics Limited Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.17 | 9.89 | 1.73 |
| Quick Ratio | 3.66 | 9.89 | 1.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.95 Million | $5.39 Million | $2.03 Million |
CytoMed Therapeutics Limited Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between CytoMed Therapeutics Limited Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.82 |
| Latest Market Cap to Assets Ratio | 1.20 |
| Asset Growth Rate (YoY) | -20.7% |
| Total Assets | $7.98 Million |
| Market Capitalization | $9.58 Million USD |
Valuation Analysis
Above Book Valuation: The market values CytoMed Therapeutics Limited Ordinary Shares's assets above their book value (1.20x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: CytoMed Therapeutics Limited Ordinary Shares's assets decreased by 20.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
The table below shows the annual total assets of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.98 Million | -20.67% |
| 2024-12-31 | $10.07 Million | -18.84% |
| 2023-12-31 | $12.40 Million | +136.18% |
| 2022-12-31 | $5.25 Million | -13.87% |
| 2021-12-31 | $6.10 Million | +59.45% |
| 2020-12-31 | $3.82 Million | +29.90% |
| 2019-12-31 | $2.94 Million | -- |
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I… Read more